<DOC>
	<DOCNO>NCT03004131</DOCNO>
	<brief_summary>This study ass onset action fix drug combination azelastine hydrochloride fluticasone propionate nasal spray ( MP-AzeFlu ) treat nasal symptom seasonal allergic rhinitis ( SAR ) induce allergen challenge Environmental Exposure Chamber ( EEC ) .</brief_summary>
	<brief_title>MP-AzeFlu Allergen Chamber - Onset Action Study</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<criteria>1 . Provide write informed consent . 2 . Male female subject ( childbearing nonchildbearing potential , defined female menstruation minimum 12 month prior screen ) age 18 55 year ( inclusive ) screening . 3 . History SAR ragweed pollen least previous 2 ragweed pollen season . 4 . Positive skin prick test ( SPT ) response ragweed pollen ( allergen induce wheal diameter least 3 mm large negative control ) . A test perform previous 12 month may use qualify subject . To eligible Visit 2 EEC , subject must additionally comply follow criterion : 5 . Asymptomatic mild symptom baseline record symptom prior start screen EEC ( Visit 2 ) : TNSS ≤ 3/12 score symptom less 2 . To eligible Visit 3 , subject must additionally comply follow criterion Visit 2 EEC : 6 . Demonstrate adequate symptomology : TNSS ≥ 6/12 least two ePDAT™ time point assessment hour 02 EEC ( Visit 2 ) , least one occur last two time point . Additionally , subject require meet score least 2/3 runny nose least twice hour 02 EEC , least one occur last two time point . To eligible randomisation ( Visit 3 ) , subject must additionally comply follow criterion : 7 . Demonstrate adequate symptomology : TNSS ≥ 6/12 least two ePDAT™ time point assessment hour 02 EEC ( Visit 3 ) , least one occur last two time point . Additionally , subject require meet score least 2/3 runny nose least twice hour 02 EEC , least one occur last two time point . No evidence complete nasal blockage either one side anterior rhinoscopy within 30 minute prior dose . Safety concern : 1 . History allergic reaction fluticasone propionate , azelastine hydrochloride , loratadine , one excipients study treatment ( e.g . benzalkonium chloride , phenylethyl alcohol , microcrystalline cellulose ) component container . 2 . History anaphylaxis , cardiovascular , pulmonary , hepatic , renal , gastrointestinal , haematological , endocrine , metabolic , psychiatric , neurological , disease screening may affect subject safety study evaluation study endpoint discretion Investigator and/or designee . 3 . Subjects current diagnosis asthma subject measure FEV1 &lt; 75 % predict value . 4 . Pregnant , breastfeed plan pregnancy study woman childbearing potential use adequate contraception . Women childbearing potential abstinent use highly effective method birth control define result low failure rate ( i.e . &lt; 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , hormonal IUDs , tubal ligation vasectomise partner start least 4 week prior screen . Lack suitability study : 5 . Previous concomitant treatment : use prohibit therapy ( Antihistaminic agent , Theophylline , Cromolyn sodium , Corticosteroids , Decongestants , Immunotherapy , Systemic antibiotic , cytochrome P450 3A4 inhibit induce drug [ e.g . ritonavir , ketoconazole , itraconazole , erythromycin , cimetidine , rifampicin , St. John 's wort ( Hypericum perforatum ) etc . ] , Tricyclic antidepressants MAO inhibitor ) ; use medication consider influence outcome study EEC session , discretion Investigator and/or designee . 6 . Subjects ( expect ) clinically relevant symptom time schedule EEC assessment due concomitant sensitization , i.e. , positive SPT ( mean wheal diameter least 3 mm large negative control ) history allergic response causative allergen , discretion Investigator . Subjects positive SPT cat and/or dog acceptable subject avoids cat and/or dog duration study . 7 . Concomitant disease : abnormality screen visit might interfere study result determine Investigator and/or designee . 8 . Presence severely deviate septum , septal perforation , structural nasal defect large nasal polyp cause obstruction determine Investigator . 9 . Acute condition : acute illness within 7 day prior screen visit , include acute conjunctivitis ocular infection . 10 . History increase ocular pressure , glaucoma and/or cataract . 11 . Tuberculosis , untreated local systemic fungal bacterial infection , systemic viral parasitic infection ocular herpes simplex . 12 . Recent nasal ulcer , mucosal erosion , nasal surgery , nasal trauma , judge Investigator . 13 . Exposure chickenpox measles within 4 week prior screen visit study . 14 . History chronic sinusitis history nonallergic rhinitis . 15 . Exposure another investigational product within last 30 day prior screen . 16 . History malignancy within past five year , except basal cell skin carcinoma treat recurrence least 3 month . 17 . Neurological psychiatric disease drug alcohol abuse would interfere subject 's proper completion protocol assignment . Subjects positive urine drug screen exclude . 18 . Subjects undergoing surgical procedure general anaesthesia within 90 day prior screen plan undergo surgery/hospitalization study . Administrative reason : 19 . Vulnerable subject ( person keep detention ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>